Mr. Rumble has more than 25 years of executive level experience in the
global medical sterilization sector
Ticker Symbol: TOS/TSX
Shares Outstanding: 47,863,402
QUEBEC CITY, Oct. 6 /CNW Telbec/ - Germain Carrière, the Chairman of the
Board of TSO3 Inc. ("TSO3") (TSX: TOS) is pleased to announce the appointment
of Ric Rumble as President and Chief Executive Officer of the Company
effective October 14, 2008. Mr. Rumble, who prior to this appointment held the
position of President of BERCHTOLD Corporation, has more than 25 years of
executive experience in the North American and global medical device industry.
"TSO3 is pleased and excited to welcome Ric Rumble to his new position as
President and CEO," said Mr. Carrière. "He has a long and impressive track
record in the medical device industry, including delivering significant and
sustained revenue and earnings growth, leading successful new commercial
strategies and negotiating and integrating large-scale acquisitions. With this
background and expertise, I am sure that Ric will bring TSO3 strong and
inspired leadership to the benefit of the Company and its shareholders," said
To ensure a smooth leadership transition, Mr. W. Barry McDonald, who has
held the position of Interim President and Chief Executive Officer since last
May, will stay on with the Company in an advisory role to the new CEO and the
Board for a brief period.
"I am prepared and enthusiastic to take on this new challenge and to
continue the momentum generated from the recently implemented sales, operating
and R&D initiatives," said Mr. Rumble. "I believe that with its innovative and
effective sterilization technology, TSO3 has great potential to become a key
player in the medical instrument sterilization sector. The market for this
technology is significant, and TSO3's patented ozone sterilization process
offers an economical, safe and environmentally friendly alternative to other
low temperature sterilization methods widely in use at many hospitals. As
President and CEO, I look forward to providing the strategic leadership
required to enable TSO3 to achieve its short and long-term growth objectives,"
Mr. Rumble holds a Bachelors of Science degree in biology and an Honour's
Bachelors of Science in microbiology and immunology from the University of
Western, Ontario. For 25 years he has held a variety of management and
executive positions at leading medical device manufacturers in Canada and the
United States. These previous positions include: President of BERCHTOLD
Corporation, Vice President, Sales & Marketing for Strategic Diagnostics Inc.,
Vice President and General Manager of STERIS Corporation and President and
Chief Executive Officer of MediVators Inc. For several years, Mr. Rumble also
worked for 3M Company in various management positions, including Global
Business Unit Manager, Sterile Processing.
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology with high commercial potential. The Company's first product, the
Sterizone(R) 125L Ozone Sterilizer, is designed for sterile processing centers
in the hospital environment.
In contrast to other methods used, the ozone sterilization process
developed and patented by TSO3 meets all standards required by the evolution
in sterilization needs, which are: significant costs savings, increased safety
for patients and hospital staff, and a "green" environmentally safe process.
The Company believes that its technology represents an advantageous
replacement solution to other low temperature sterilization processes
currently used in hospitals.
The Sterizone(R) 125L Ozone Sterilizer is cleared for commercialization
by the US Food and Drug Administration and by Health Canada. TSO3 has been in
the commercialization phase for this first product since 2006.
For more information about TSO3, visit the Company's Web site at
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Marc Boisjoli, CFO, (418) 651-0003, ext. 228,
email@example.com; Frédéric Tremblay, HKDP, (514) 395-0375, ext. 234; Source: